MDACC Study No:2007-0869 ( NCT No: NCT00631631)
Title:Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-risk Osteosarcoma
Principal Investigator:Peter M. Anderson
Treatment Agent:Liposomal MTP-PE
Study Status:Terminated
Study Description:The goal of the compassionate access study is to provide an investigational
drug, liposomal muramyl tripeptide phosphatidyl ethanolamine (L-MTP-PE) alone
or combined with recommended approved therapy to you for treatment of
osteosarcoma. Compassionate access is a way to make a drug that showed an
improvement in survival responses available while it is still being tested.
Hide details for General InformationGeneral Information

Disease Group:Bone; Pediatrics
Phase of Study:N/A
Treatment Agents:Liposomal MTP-PE
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:Hospitalization is not anticipated for L-MTP-PE; it is an outpatient 1 hour
infusion. The protocol stipulates that L-MTP-PEshould be used with outpatient
chemotherapy regimens. However, patients in the hospital for other reasons may
get L-MTP-PE.
Supported By:Millennium: the Takeda Oncology Company.
Return Visit:Maximum: 36 weeks total: Twice weekly for 12 weeks, then once weekly for 24
additional weeks.
Patients may recieve some treatment at a participating center other than MDACC.
Home Care:Supportive medications may be given at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Peter M. Anderson
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults